RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+43%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$926M
AUM Growth
+$926M
(+30%)
Cap. Flow
-$7.41M
Cap. Flow
% of AUM
-0.8%
Top 10 Holdings %
Top 10 Hldgs %
29.66%
Holding
99
New
14
Increased
25
Reduced
45
Closed
5
Top Buys
| 1 |
Gilead Sciences
GILD
|
$17.7M |
| 2 |
LVGO
Livongo Health, Inc. Common Stock
LVGO
|
$9.4M |
| 3 |
Baxter International
BAX
|
$8.18M |
| 4 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$8.1M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$7.8M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$13.9M |
| 2 |
MacroGenics
MGNX
|
$9.07M |
| 3 |
Esperion Therapeutics
ESPR
|
$8.61M |
| 4 |
Neurocrine Biosciences
NBIX
|
$6.71M |
| 5 |
Nektar Therapeutics
NKTR
|
$6.6M |
Sector Composition
| 1 | Healthcare | 94.86% |
| 2 | Communication Services | 1.03% |
| 3 | Energy | 0.07% |
| 4 | Technology | 0.06% |
| 5 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Thermo Fisher Scientific
TMO
$183B
| $6.88M | 0.74% |
19,000
| – | – |
|
52
Zimmer Biomet
ZBH
$20.8B
| $6.8M | 0.74% |
58,710
-23,690
| -29% | -$2.75M |
|
|
BLUE
53
DELISTED
bluebird bio
BLUE
| $6.58M | 0.71% |
8,322
+3,150
| +61% | +$2.49M |
|
54
Sangamo Therapeutics
SGMO
$161M
| $6.05M | 0.65% |
675,000
-25,000
| -4% | -$224K |
|
55
Alkermes
ALKS
$4.95B
| $6.02M | 0.65% |
310,000
-89,000
| -22% | -$1.73M |
|
56
FibroGen
FGEN
$48.4M
| $5.88M | 0.63% |
5,800
-4,200
| -42% | -$4.26M |
|
|
SILK
57
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $5.87M | 0.63% |
140,000
-35,000
| -20% | -$1.47M |
|
58
Apellis Pharmaceuticals
APLS
$3.51B
| $5.39M | 0.58% |
165,000
+65,000
| +65% | +$2.12M |
|
59
Glaukos
GKOS
$5.42B
| $5.38M | 0.58% |
140,000
-25,000
| -15% | -$961K |
|
|
RVNC
60
DELISTED
Revance Therapeutics, Inc.
RVNC
| $5.37M | 0.58% |
220,000
| – | – |
|
61
Becton Dickinson
BDX
$54.3B
| $5.03M | 0.54% |
21,525
+7,175
| +50% | +$1.68M |
|
62
Agios Pharmaceuticals
AGIO
$2.36B
| $4.81M | 0.52% |
90,000
-20,000
| -18% | -$1.07M |
|
63
Ultragenyx Pharmaceutical
RARE
$3.04B
| $4.81M | 0.52% |
61,500
-7,024
| -10% | -$549K |
|
|
AIMT
64
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $4.76M | 0.51% |
285,000
+120,000
| +73% | +$2.01M |
|
|
GTHX
65
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $4.61M | 0.5% |
190,000
-60,172
| -24% | -$1.46M |
|
66
Biogen
BIIB
$20.8B
| $4.55M | 0.49% |
17,000
-8,000
| -32% | -$2.14M |
|
|
RDUS
67
DELISTED
Radius Health, Inc.
RDUS
| $4.52M | 0.49% |
331,826
+36,826
| +12% | +$502K |
|
|
EPZM
68
DELISTED
Epizyme, Inc
EPZM
| $4.26M | 0.46% |
265,000
-85,000
| -24% | -$1.37M |
|
69
Omnicell
OMCL
$1.51B
| $4.24M | 0.46% |
60,000
-26,095
| -30% | -$1.84M |
|
70
Incyte
INCY
$17B
| $4.16M | 0.45% |
40,000
-10,000
| -20% | -$1.04M |
|
|
MNTA
71
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $3.99M | 0.43% |
120,000
-1,400
| -1% | -$46.6K |
|
72
MeiraGTx Holdings
MGTX
$590M
| $3.76M | 0.41% |
300,000
+53,693
| +22% | +$672K |
|
|
AMRN
73
Amarin Corp
AMRN
$311M
| $3.63M | 0.39% |
26,250
-1,250
| -5% | -$173K |
|
74
Rigel Pharmaceuticals
RIGL
$710M
| $3.18M | 0.34% |
173,618
| – | – |
|
|
MYOV
75
DELISTED
Myovant Sciences Ltd.
MYOV
| $3.09M | 0.33% |
+150,000
| New | +$3.09M |
|